EVT801, Kazia’s second programme, and capital markets

EVT801, Kazia’s second programme, and capital markets

Kazia Therapeutics — 9 videos in collection

More on this equity

In the third part of our Edison TV series on Kazia Therapeutics (KZIA), John Friend, CMO, and James Garner, CEO, discuss the company’s second pipeline asset, EVT801. EVT801 is a small molecule inhibitor of VEGFR3, which preclinical data have shown to be active against a broad range of tumour types and provided compelling evidence of synergy with immunoncology agents.

Additionally, Karen Krumeich, CFO, discusses Kazia’s focus on increasing awareness of the company in the US capital markets. 2022 is a data-rich year for Kazia and this episode concludes with an overview of the anticipated milestones and catalysts.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free